Legal & General Group
CGEM icon

Legal & General Group’s Cullinan Oncology CGEM Stock Holding History

Legal & General Group’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$500K Buy
27,477
+8,776
+47% +$130K ﹤0.01% 2399
2026
Q1 		$266K Sell
18,701
-9,927
-35% -$128K ﹤0.01% 2486
2025
Q4 		$296K Buy
28,628
+13,333
+87% +$120K ﹤0.01% 2534
2025
Q3 		$90.7K Sell
15,295
-3,563
-19% -$26.1K ﹤0.01% 2647
2025
Q2 		$142K Sell
18,858
-23,950
-56% -$192K ﹤0.01% 2611
2025
Q1 		$324K Hold
42,808
– – ﹤0.01% 2528
2024
Q4 		$521K Buy
42,808
+1,315
+3% +$18.9K ﹤0.01% 2442
2024
Q3 		$695K Buy
41,493
+2,242
+6% +$39.8K ﹤0.01% 2355
2024
Q2 		$685K Buy
39,251
+19,690
+101% +$419K ﹤0.01% 2317
2024
Q1 		$333K Buy
19,561
+5,552
+40% +$85.8K ﹤0.01% 2577
2023
Q4 		$143K Hold
14,009
– – ﹤0.01% 2739
2023
Q3 		$127K Sell
14,009
-562
-4% -$5.85K ﹤0.01% 2801
2023
Q2 		$157K Buy
14,571
+7,921
+119% +$84.1K ﹤0.01% 2791
2023
Q1 		$68K Buy
6,650
+635
+11% +$7K ﹤0.01% 2831
2022
Q4 		$63.5K Hold
6,015
– – ﹤0.01% 2906
2022
Q3 		$77K Buy
6,015
+371
+7% +$5K ﹤0.01% 2886
2022
Q2 		$72K Sell
5,644
-875
-13% -$9.92K ﹤0.01% 2927
2022
Q1 		$68K Hold
6,519
– – ﹤0.01% 2946
2021
Q4 		$101K Buy
6,519
+775
+13% +$15.5K ﹤0.01% 2905
2021
Q3 		$130K Buy
5,744
+3,549
+162% +$94.9K ﹤0.01% 2796
2021
Q2 		$56K Buy
2,195
+840
+62% +$25.8K ﹤0.01% 2916
2021
Q1 		$56K Buy
+1,355
New +$55K ﹤0.01% 2787

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Legal & General Group's CGEM Position: Q2 2026 in Review

Legal & General Group increased its Cullinan Oncology (CGEM) stake by 47% in Q2 2026, buying an estimated $130K and bringing the position to 27,477 shares worth $500K. The position accounts for ﹤0.01% of the portfolio, ranked #2399.

Legal & General Group first reported a position in CGEM in Q1 2021 and has held it in 22 quarters since. The position peaked at $695K in Q3 2024. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Legal & General Group held 27,477 shares of Cullinan Oncology worth $500K as of Q2 2026.
  • Legal & General Group bought 8,776 Cullinan Oncology shares in Q2 2026, an estimated $130K.
  • Cullinan Oncology made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2399 holding.
  • Legal & General Group first reported a position in Cullinan Oncology in Q1 2021 and has held it in 22 quarters since.
  • Legal & General Group's Cullinan Oncology position peaked at $695K in Q3 2024.
  • 183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.